Long-term evaluation of blood silicon and ostecalcin in operatively treated patients with benign bone tumors using bioactive glass and autogenous bone

2008 ◽  
Vol 87B (1) ◽  
pp. 73-76 ◽  
Author(s):  
N. C. Lindfors ◽  
J. T. Heikkilä ◽  
A. J. Aho
Keyword(s):  
Bioactive Glass ◽  
Bone Tumors ◽  
Autogenous Bone ◽  
Benign Bone Tumors ◽  
Term Evaluation

Bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors

2008 ◽  
Vol 90B (1) ◽  
pp. 131-136 ◽  
Author(s):  
Nina C. Lindfors ◽  
Jouni T. Heikkilä ◽  
Ilona Koski ◽  
Kimmo Mattila ◽  
Allan J. Aho
Keyword(s):  
Bioactive Glass ◽  
Bone Graft ◽  
Bone Tumors ◽  
Autogenous Bone ◽  
Benign Bone Tumors ◽  
Bone Graft Substitutes

scholarly journals Preliminary results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions

Open Medicine ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. 487-492 ◽  
Author(s):  
Daniel Kotrych ◽  
Szymon Korecki ◽  
Paweł Ziętek ◽  
Bartosz Kruk ◽  
Agnieszka Kruk ◽  
...  
Keyword(s):  
Bone Substitute ◽  
Bone Tumors ◽  
Bone Cyst ◽  
Bone Diseases ◽  
Long Term Results ◽  
Reconstructive Procedures ◽  
Benign Bone Tumors ◽  
Significant Clinical Improvement ◽  
Tumor Like Lesions

AbstractBackground: CERAMENT™|BONE VOID FILLER is an injectable and moldable ceramic bone substitute material intended for bone voids. The material consists of hydroxyapatite and calcium sulfate hemihydrate. The aim of this study is to present the first long-term results following open curettage of benign bone tumors and tumor-like lesions and void filling with this novel injectable and synthetic bone graft. Methods: Thirty three patients were enrolled into the study between June 2013 and October 2014 .Totally, we treated 24 women and 9 men with a median age of 47 years (range: 22-74). All patients suffered from primary musculoskeletal system disorders (enchondroma 63,6%, giant cell tumor 18%, aneurysmal bone cyst 9%, fibrous dysplasia 9%, Gaucher disease 3%). We performed curettage of pathological lesions, then the bone substitute was administered by means of needle to the void. Results: The average follow-up was 13 months (range: 2-13 months, median 10 months). No metastasis or recurrence had been detected. We received significant clinical improvement relating to VAS, MSTS, and oncological results. Conclusions: The results of our study report that CERAMENT can be successfully used as a bone substitute in patients with various bone diseases, as well as benign bone tumors. CERAMENT can provide an effective and long-term solution for reconstructive procedures following curettage of bone tumors and tumor like lesions.

Bisphosphonate therapy for unresectable symptomatic benign bone tumors: A long-term prospective study of tolerance and efficacy

Bone ◽  
2014 ◽  
Vol 58 ◽  
pp. 11-16 ◽  
Author(s):  
F. Cornelis ◽  
M.E. Truchetet ◽  
N. Amoretti ◽  
D. Verdier ◽  
C. Fournier ◽  
...  
Keyword(s):  
Prospective Study ◽  
Bone Tumors ◽  
Bisphosphonate Therapy ◽  
Benign Bone Tumors

scholarly journals Clinical observation of mineralized collagen bone grafting after curettage of benign bone tumors

2020 ◽  
Vol 7 (6) ◽  
pp. 567-575
Author(s):  
Chong Gao ◽  
Zhi-Ye Qiu ◽  
Jian-Wen Hou ◽  
Wei Tian ◽  
Jian-Ming Kou ◽  
...  
Keyword(s):  
Bone Defect ◽  
Bone Grafting ◽  
Bone Tumors ◽  
Statistical Difference ◽  
Bone Matrix ◽  
Autogenous Bone ◽  
Allogeneic Bone ◽  
Musculoskeletal Tumor Society ◽  
Benign Bone Tumors ◽  
Mineralized Collagen

Abstract Curettage of benign bone tumor is a common cause for bone defect. For such bone defect repair, autogenous bone, allogeneic bone and traditional artificial bone graft substitutes have many disadvantages. In recent years, a biomimetic mineralized collagen (MC) with similar composition and microstructures to the natural bone matrix was developed and used for treating various bone defects. In this work, a retrospective study analyzed clinical outcomes of patients treated with curettage of benign bone tumors and bone grafting with MC, in comparison to another group treated with the same surgical method and autogenous bone. Lane–Sandhu X-ray score of the autogenous bone group was superior to the MC group at 1 month after the operation, but the two groups had no statistical difference at 6 and 12 months. The MC group was better in Musculoskeletal Tumor Society scoring at 1 and 6 months after the operation, and the two groups had no statistical difference at 12 month. Therefore, the MC performed not as good as autogenous bone in early stage of bone healing but achieved comparable outcomes in long-term follow-ups. Moreover, the MC has advantages in function recovery and avoided potential complications induced by harvesting autogenous bone.

scholarly journals Packing of Hydroxyapatite Alone Versus Autogenous Bone Graft for the Treatment of Benign Bone Tumors or Bone Cysts.

1998 ◽  
Vol 47 (3) ◽  
pp. 1037-1041
Author(s):  
Osamu Inoue ◽  
Hideyuki Sakamoto ◽  
Naoyuki Matsuda ◽  
Hiroki Maehara ◽  
Kunio Ibaraki
Keyword(s):  
Bone Graft ◽  
Bone Tumors ◽  
Autogenous Bone Graft ◽  
Autogenous Bone ◽  
Bone Cysts ◽  
Benign Bone Tumors
Sign in / Sign up

Export Citation Format

Share Document